DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration
Silver Spring MD 20993

NDA 20415/S-030
NDA 21208/S-020

SUPPLEMENT APPROVAL/
FULFILLMENT OF POSTMARKETING REQUIREMENT

Organon USA Inc.
Attention: Siyoung Ahn, Associate Director, Worldwide Regulatory Affairs
126 East Lincoln Avenue, P.O. Box 2000
Rahway, NJ 07065

Dear Ms. Ahn:

Please refer to your Supplemental New Drug Applications (sNDA) dated October 4, 2013, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Remeron (mirtazapine) 15 mg, 30 mg, and 45 mg Tablets (NDA 20415) & Remeron SolTab (mirtazapine) 15 mg, 30 mg, and 45 mg orally disintegrating tablets (NDA 21208).

We acknowledge receipt of your amendment dated December 18, 2015, which constituted a complete response to our July 16, 2014, action letter.

These Prior Approval supplemental new drug applications propose revisions to the Warnings, Precautions, Adverse Reactions, and Overdosage sections as well as the Medication Guide based upon the results of your Postmarketing Requirement study report.

APPROVAL & LABELING

We have completed our review of these supplemental applications, as amended. They are approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm. Content of labeling must be identical to the enclosed labeling (text for the package insert), with the

addition of any labeling changes in pending "Changes Being Effected" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled "SPL Standard for Content of Labeling Technical Qs and As at http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf

The SPL will be accessible from publicly available labeling repositories.
Also within 14 days, amend all pending supplemental applications that includes labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

FULFILLMENT OF POSTMARKETING REQUIREMENT

Your December 18, 2015, submission contained the final report for the following postmarketing requirement listed in the July 16, 2014, Agency letter.

2176-1 A single-center randomized, placebo-controlled and active-controlled thorough QT (TQT) trial of Remeron (mirtazapine) in normal (or healthy) subjects. Please refer to ICH E14 guidance to design the trial and submit the protocol to the agency for comments. The doses studied should ensure the clinical concentration response relationship for QTc prolongation is characterized, including exploration of higher concentrations than those achieved following the anticipated therapeutic dose at the steady state. Include the highest tolerable dose in the trial.

We have reviewed your submission and conclude that the above requirement was fulfilled.

This completes all of your postmarketing requirements acknowledged in our July 16, 2014, letter.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, contact Hiren Patel, Regulatory Project Manager, at hiren.patel@fda.hhs.gov.

Sincerely,

{See appended electronic signature page}

Mitchell V. Mathis, M.D.
Director
Division of Psychiatry Products
Office of Drug Evaluation I
Center for Drug Evaluation and Research

ENCLOSURE:
Content of Labeling

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

MITCHELL V Mathis
07/08/2016